C12N 2760/16334
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/16334 (Use of virus or viral component as vaccine) appears on 30 US grants and 51 published applications in this corpus.
Search patents in C12N- Granted patents
- 30
- Published applications
- 51
- Assignees
- 28
- Inventors
- 81
- Latest grant
- 7 Oct 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2007 | 0 | 2 |
| 2008 | 0 | 2 |
| 2009 | 0 | 1 |
| 2010 | 1 | 1 |
| 2011 | 0 | 1 |
| 2012 | 0 | 1 |
| 2013 | 2 | 6 |
| 2014 | 2 | 2 |
| 2015 | 4 | 5 |
| 2016 | 3 | 4 |
| 2017 | 0 | 2 |
| 2018 | 4 | 4 |
| 2019 | 0 | 5 |
| 2020 | 2 | 2 |
| 2021 | 5 | 0 |
| 2022 | 1 | 8 |
| 2023 | 1 | 2 |
| 2024 | 2 | 1 |
| 2025 | 3 | 1 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Nanoparticle-based influenza virus vaccines and uses thereof7 Oct 2025US 12,433,943 B2The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Human antibodies to Fel d1 and methods of use thereof18 Mar 2025US 12,252,530 B2Regeneron Pharmaceuticals, Inc.
- Influenza vaccines25 Feb 2025US 12,234,263 B2InvVax, Inc.
- Stabilized hemagglutinin (HA) trimers as influenza vaccine antigens8 Oct 2024US 12,109,261 B1The Scripps Research Institute
- Production of viruses in cell culture6 Aug 2024US 12,054,750 B2Commonwealth Scientific and Industrial Research Organisation
- Vaccination using high-density microprojection array patch17 Sep 2026US 2026/0273256 A1Vaxxas Pty Limited
- Production of viruses in cell culture9 Jan 2025US 2025/0011731 A1Commonwealth Scientific and Industrial Research Organisation
- Multivalent influenza vaccines15 Aug 2024US 2024/0269258 A1Sanofi Pasteur Limited
- Influenza vaccines28 Dec 2023US 2023/0416311 A1InvVax, Inc.
- Multivalent influenza vaccines9 Feb 2023US 2023/0043128 A1Sanofi
Most cited
By later US patents
- Human antibodies to Fel d1 and methods of use thereof31US 9,079,948 B2Regeneron Pharmaceuticals, Inc. · 2015
- Yeast-based vaccine for inducing an immune response25US 7,736,642 B2GlobeImmune, Inc. · 2010
- Compositions that include hemagglutinin14US 8,420,102 B2VaxInnate Corporation · 2013
- Methods of making hemagglutinin proteins10US 9,056,901 B2VaxInnate Corporation · 2015
- Process for stabilizing an adjuvant containing vaccine composition8US 8,551,527 B2Sanofi Pasteur Limited · 2013